MedTrace Logo

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

NCT04826107 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2021-04-01

No results posted yet for this study

Summary

This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.

Conditions

Interventions

DRUG

DP303c treatment

DP303c injection, every 3 weeks.

DRUG

DP303c treatment（second-line of HER2-positive）

DP303c injection, every 3 weeks.

DRUG

DP303c treatment （third-line of HER2-positive）

DP303c injection, every 3 weeks.

DRUG

DP303c treatment（≥second-line of HER2 low expressing）

DP303c injection, every 3 weeks.

DRUG

DP303c + PD-1/PD-L1 treatment

DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xu JianMing, Ph.D · Chinese PLA General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2024-08-31
Completion
2024-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826107 on ClinicalTrials.gov